Long-awaited details of the NHS Long Term Plan, which is to be funded by a government investment of £20.5 billion a year in real terms by 2023/24 - have now been unveiled, with the promise of saving almost half a million more lives.
Janssen has submitted an application to the European Medicines Agency (EMA) seeking to expand the approval of Stelara to include the treatment of adults with moderately to severely active ulcerative colitis (UC).
An Independent Data Monitoring Committee (IDCM) has recommended that Amryt’s pivotal Phase III EASE trial for AP101 - a potential treatment for Epidermolysis Bullosa (EB) - should continue, raising hopes for a new therapy for the condition.
In advance of the UK leaving the European Union on 29 March 2019, the Medicines and Healthcare products Regulatory Agency (MHRA) has released a statement detailing its preparations for the event of a no-deal Brexit scenario.
The National Institute for Health and Care Excellence (NICE) has recommended that a potentially life-changing treatment be available to people with a severe form of asthma on the NHS in England and Wales.
The US Food and Drug Administration has approved the new treatment Sprycel for children one year of age and older, facing a type of blood cancer known as Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) when used in combination with chemotherapy.
Entry for the PharmaTimes International Clinical Researcher of the Year competition will close for entry on the 31st January. Entries are already surpassing this time last year so enter now and join them.